Lévothyroxine et liothyronine : interactions médicamenteuses

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (notice Brimonidine et timolol, Mises en garde et précautions)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (notice Choriogonadotropine alfa, Contre-indications)

Clomiphene citrate tablets are contraindicated in patients with uncontrolled thyroid or adrenal dysfunction or in the presence of an organic intracranial lesion such as pituitary tumor (see INDICATIONS AND USAGE). (notice Clomifène, Contre-indications)

When concomitant administration of corticosteroids and levothyroxine is required, administration of corticosteroid should precede the initiation of levothyroxine therapy to avoid adrenal crisis. (notice Dexaméthasone, Mises en garde et précautions)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (notice Dorzolamide et timolol, Mises en garde et précautions)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. (notice Dulaglutide, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Reactions including anaphylaxis have been reported [see Adverse Reactions (6.2) ] High levels of FSH indicating primary gonadal failure Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders) [see Indications and Usage (1.1 , 1.2 , 1.3) ] Hypersensitivity reactions to streptomycin or neomycin. (notice Follitropine, Contre-indications)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Do not take thyroid hormone replacement therapy within 2 hours of dosing with LANTHANUM CARBONATE. (notice Lanthane, Interactions médicamenteuses)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. (notice Liraglutide, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a thyroid storm. (notice Nadolol, Mises en garde)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-blockade which might precipitate a thyroid crisis. (notice Pindolol, Mises en garde)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Avoid abrupt withdrawal of beta-blockade, which may precipitate a thyroid storm. (notice Propranolol, Mises en garde et précautions)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (notice Sémaglutide, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Thyroid Abnormalities Avoid abrupt withdrawal of beta-blockade which might be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. (notice Sotalol, Mises en garde et précautions)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (notice Timolol, Mises en garde et précautions)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (notice Tirzépatide, Mise en garde encadrée)

People who have thyroid problems (hyperthyroidism) may have a higher chance of having a hypertensive crisis. (notice Tranylcypromine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (notice Lévothyroxine et liothyronine, Mise en garde encadrée)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Abrupt withdrawal of β-blockade may precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom acebutolol therapy is to be withdrawn should be monitored closely. (notice Acébutolol, Mises en garde)

Levothyroxine The bioavailability of alendronate was slightly decreased when BINOSTO and levothyroxine were co-administered to healthy subjects [see Clinical Pharmacology (12.3) ] . (notice Acide alendronique, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Thyroid Abnormalities Nexterone inhibits peripheral conversion of throxine (T4) to triiodothyronine (T3) and may cause increased T3 levels, and increased levels of inactive reverse T3 (rT3) in clinically euthyroid patients. (notice Amiodarone, Mises en garde et précautions)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom TENORMIN therapy is to be withdrawn should be monitored closely. (notice Aténolol, Mises en garde)

Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom atenolol and chlorthalidone therapy is to be withdrawn should be monitored closely. (notice Aténolol et chlortalidone, Mises en garde)

Monitor thyroid function before initiation of, and periodically throughout, treatment with INLYTA. (notice Axitinib, Mises en garde et précautions)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

Abrupt withdrawal of beta-blockade might precipitate a thyroid storm; therefore, patients known or suspected of being thyrotoxic from whom betaxolol is to be withdrawn should be monitored closely (see Dosage and Administration: Cessation of therapy ). (notice Bétaxolol, Mises en garde)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Monitor and replace thyroid hormone if needed. (notice Bexarotène, Mises en garde et précautions)

Laboratory Test Interactions Based on reports involving thiazides, bisoprolol fumarate and hydrochlorothiazide tablets may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. (notice Bisoprolol et hydrochlorothiazide, Précautions)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

Concomitant use with colesevelam hydrochloride may decrease the exposure of the following drugs: Drugs with a narrow therapeutic index (e.g., cyclosporine), phenytoin, thyroid hormone replacement therapy, warfarin, oral contraceptives containing ethinyl estradiol and norethindrone, olmesartan medoxomil, and sulfonylureas (glimepiride, glipizide, glyburide). (notice Colésévélam, Interactions médicamenteuses)

Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (notice Colestyramine, Interactions médicamenteuses)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Other metabolic events include a reduction in thyroid binding globulin and T4 with increased uptake of T3, but without disturbance of thyroid stimulating hormone or of free thyroxin index. (notice Danazol, Précautions)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

In patients with thyroid disease or those taking thyroid medication, because of the possibility of cardiovascular toxicity, including arrhythmias. e. (notice Désipramine, Mises en garde)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (notice Digoxine, Mises en garde et précautions)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Abnormal Thyroid Function Tests Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM. (notice Eslicarbazépine, Mises en garde et précautions)

Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, monitor patients for signs of thyrotoxicosis when withdrawing beta blocking therapy. (notice Esmolol, Mises en garde et précautions)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Thyroid hormones High-doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels. (notice Furosémide, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

…recommended that appropriate references first be consulted to determine the usual precautions for the use of the other drug; e.g., when epinephrine is injected along with hyaluronidase, the precautions for the use of epinephrine in cardiovascular disease, thyroid disease, diabetes, digital nerve block, ischemia of the fingers and toes etc., should be observed. (notice Hyaluronidase, Interactions médicamenteuses)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

…levels of the drug; Patients with history of urinary retention, or history of narrow-angle glaucoma because of the drug's anticholinergic properties; hyperthyroid patients or those on thyroid medication because of the possibility of cardiovascular toxicity; patients with a history of seizure disorder because this drug has been shown to lower the seizure threshold;… (notice Imipramine, Mises en garde)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Thyroid function should be monitored periodically. (notice Interféron bêta-1a, Mises en garde et précautions)

Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (notice Lanréotide, Mises en garde et précautions)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (notice Lithium, Mises en garde et précautions)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (notice Octréotide, Mises en garde et précautions)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (notice Orlistat, Mises en garde et précautions)

Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (notice Pasiréotide, Mises en garde et précautions)

Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (notice Pazopanib, Mises en garde et précautions)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Hypothyroidism Adults: Clinical trials with quetiapine demonstrated dose-related decreases in thyroid hormone levels. (notice Quétiapine, Mises en garde et précautions)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Substitute non-enzyme inducing therapies at least 2 weeks prior to initiation of irinotecan therapy Decrease irinotecan and active metabolite exposure Levothyroxine Decrease exposure Losartan Parent Decrease AUC by 30% Active metabolite (E3174) Decrease AUC by 40% Methadone In patients well-stabilized on methadone, concomitant administration of rifampin resulted… (notice Rifampicine, Interactions médicamenteuses)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (notice Rifapentine, Interactions médicamenteuses)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy (e.g., cyclosporine, tacrolimus, levothyroxine), consider separation of the timing of the administration of the two drugs [see Clinical Pharmacology (12.3) ] . (notice Sévélamer, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (notice Somatropine, Mises en garde et précautions)

• Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (notice Sorafénib, Mises en garde et précautions)

• Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (notice Sunitinib, Mises en garde et précautions)

Drug-Laboratory Test Interactions There are postmarketing reports of T 4 elevations in postmenopausal patients taking tamoxifen that may be explained by increases in thyroid-binding globulin. (notice Tamoxifène, Interactions médicamenteuses)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

Caution is advised in patients with history of urinary retention because of the drug's anticholinergic properties; hyperthyroid patients or those on thyroid medication because of the possibility of cardiovascular toxicity; patients with a history of seizure disorder, because this drug has been shown to lower the seizure threshold; patients receiving guanethidine… (notice Trimipramine, Mises en garde)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (notice Acide valproïque, Mises en garde et précautions)

Hypocalcemia and Mineral Metabolism Preexisting hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Reclast. (notice Acide zolédronique, Mises en garde et précautions)

Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram – see WARNINGS section. (notice Amitriptyline, Interactions médicamenteuses)

Abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. (notice Bisoprolol, Mises en garde)

Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (notice Busulfan, Mises en garde)

…dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, paliperidone, phenytoin,… (notice Carbamazépine, Interactions médicamenteuses)

Abrupt withdrawal of β-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. (notice Carvédilol, Mises en garde et précautions)

Cholestyramine or Colestipol - Cholestyramine or colestipol binds both T 4 and T 3 in the intestine, thus impairing absorption of these thyroid hormones. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Secondary malignancies (urinary tract cancer, myelodysplasia, acute leukemias, lymphomas, thyroid cancer, and sarcomas) have been reported in patients treated with cyclophosphamide-containing regimens . (notice Cyclophosphamide, Mises en garde et précautions)

Losartan, glipizide and levothyroxine did not show any changes in exposure when co-administered with LOKELMA. (notice Cyclosilicate de zirconium sodique, Interactions médicamenteuses)

Other Medications Used for the Management of Fanconi Syndrome PROCYSBI can be administered with other electrolyte and mineral replacements necessary for management of Fanconi syndrome, as well as vitamin D and thyroid hormone. (notice Cystéamine, Interactions médicamenteuses)

Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (notice Divalproate de sodium (valproate), Mises en garde et précautions)

Cases of myelodysplastic syndrome, acute leukemias, lymphomas, thyroid cancers, and sarcomas have occurred and may develop several years after chemotherapy has been discontinued. (notice Ifosfamide, Mises en garde et précautions)

Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement. (notice Imatinib, Mises en garde et précautions)

Warnings Potassium iodide can cause fetal harm, abnormal thyroid function, and goiter when administered to a pregnant woman. (notice Iodure de potassium, Mises en garde)

Thyroid Disorders Both hypothyroidism and hyperthyroidism have been reported [see Adverse Reactions (6.2) ] . (notice Lénalidomide, Mises en garde et précautions)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (notice Méthyltestostérone, Précautions)

Thyrotoxicosis: Abrupt withdrawal in patients with thyrotoxicosis might precipitate a thyroid storm. (notice Métoprolol, Mises en garde et précautions)

Abrupt withdrawal in thyrotoxicosis might precipitate a thyroid storm. (notice Métoprolol et hydrochlorothiazide, Mises en garde et précautions)

EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. (notice Minocycline, Mises en garde et précautions)

In cases of cognitive dysfunction, thyroid function should be evaluated as mitotane may induce hypothyroidism. (notice Mitotane, Mises en garde et précautions)

Abrupt withdrawal of β-blockers may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate a thyroid storm. (notice Nébivolol, Mises en garde et précautions)

Great care is required if Pamelor is given to hyperthyroid patients or to those receiving thyroid medication, since cardiac arrhythmias may develop. (notice Nortriptyline, Mises en garde)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (notice Pilocarpine, Interactions médicamenteuses)

On rare occasions, hyperthyroid patients or those receiving thyroid medication may develop arrhythmias when this drug is given. (notice Protriptyline, Mises en garde)

Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (notice Testostérone, Mises en garde et précautions)

Thyroid-stimulating hormone, total thyroxine, and thyrotropin-releasing hormone response are not affected. (notice Fénoprofène, Interactions médicamenteuses)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3)… (notice Montélukast, Interactions médicamenteuses)